10-K: Accuray Refinances Debt, Narrows Losses Amid Macro Headwinds

Accuray Incorporated has successfully refinanced its debt, significantly reducing its net loss and achieving positive cash flow from operations, despite ongoing macroeconomic challenges and tariff impacts.

Summary

• Accuray Incorporated reported a net loss of $1.6 million for fiscal year 2025, a substantial improvement from a $15.5 million net loss in fiscal year 2024.
• Net revenue increased by 3% to $458.5 million in FY2025, up from $446.5 million in FY2024, driven by growth in both product and service revenues.
• Gross profit rose by $4.0 million to $147.0 million in FY2025, maintaining a gross margin of 32.1%.
• Operating expenses decreased by 2% to $139.1 million, primarily due to lower R&D and G&A costs, partially offset by increased selling and marketing expenses.
• The company secured a new Financing Agreement on June 6, 2025, providing a $150 million Term Loan Facility, a $20 million Delayed Draw Term Loan Facility, and a $20 million Revolving Credit Facility, maturing on June 6, 2030.
• Proceeds from the new facilities were used to fully refinance existing senior secured indebtedness and to fund a $68.5 million cash payment for the exchange of a portion of the 3.75% Convertible Senior Notes due 2026.
• Approximately $18.0 million in Convertible Notes remain outstanding, due June 1, 2026.
• Warrants were issued to lenders, including 17,180,710 Premium Warrants (exercise price $1.68) and 6,247,531 Penny Warrants (exercise price $0.01), exercisable until June 6, 2032.
• Material weaknesses in internal control over financial reporting identified in FY2024 were remediated as of March 31, 2025.
• The joint venture in China (CNNC Accuray) saw increased revenues, and received NMPA approvals for its Class B device, Accuray Precision TPS, Radixact SynC, and CyberKnife S7 Systems.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant improvements in net loss and cash from operations, coupled with successful debt refinancing. However, persistent macroeconomic headwinds, tariff impacts, and the dilutive nature of the new financing temper the overall outlook.

Positives

• Net loss significantly reduced to $1.6 million in FY2025 from $15.5 million in FY2024, indicating improved financial performance.
• Cash provided by operating activities turned positive at $2.9 million in FY2025, compared to a negative $11.9 million in FY2024.
• Successful refinancing of existing debt with new credit facilities totaling $190 million (including delayed draw and revolving credit), extending maturity to June 2030.
• Remediation of previously identified material weaknesses in internal control over financial reporting as of March 31, 2025, enhancing financial reporting reliability.
• Increased net revenue by 3% year-over-year, with strong growth in China (20%) and Asia Pacific (65%) regions.
• Growth in service revenue by 4%, driven by an expanding installed base and increased spare parts purchases.
• The China joint venture received key regulatory approvals for its Class B device and advanced treatment systems, positioning for future growth in a significant market.
• Income from equity method investment increased by 156% to $4.7 million in FY2025, reflecting improved performance of the JV.

Negatives

• The company continues to operate at a net loss, albeit reduced, indicating ongoing profitability challenges.
• Cash and cash equivalents decreased to $57.4 million at June 30, 2025, from $68.6 million at June 30, 2024.
• The new debt facilities carry high interest rates (Term SOFR-based rate + 8.50% margin or Reference Rate + 7.50% margin) and include a PIK option, increasing future interest expense.
• Issuance of significant warrants (23.4 million shares) to lenders will result in future dilution for existing stockholders.
• Ongoing macroeconomic conditions, including inflation, supply chain challenges, and increased logistics costs, are expected to continue impacting gross margins and cash from operations through at least calendar year 2025.
• Reduced budgets and longer customer installation timelines in the United States are negatively impacting net revenue and are expected to continue through fiscal year 2026.
• Sales to China are expected to be adversely impacted through at least the first half of fiscal year 2026 due to tariff uncertainties.
• The company has substantial indebtedness and restrictive covenants that limit financial flexibility and could lead to default if not met.
• No payouts were made under the company bonus plan for fiscal year 2025 due to debt covenant compliance concerns and a need to conserve cash.

Risks

• Global economic environment, including inflation, recession, and currency fluctuations, could adversely affect business, financial condition, and results of operations by delaying or preventing customer financing and facility implementation.
• Failure to achieve widespread market acceptance of CyberKnife or TomoTherapy platforms could prevent necessary revenue generation.
• Inability to maintain or increase gross margins on product sales and services could hinder profitability.
• Substantial indebtedness and potential future debt may adversely affect financial condition and future financial results, with past non-compliance with financial covenants requiring waivers.
• Enhanced international tariffs, particularly between the United States and China, could decrease product sales volume in China and increase costs.
• Operating results, cash flows, quarterly orders, revenues, and margins are subject to significant fluctuations and unpredictability.
• Intense competition and rapid technological change in the medical device industry may render products obsolete or less useful.
• Risks from international operations, including economic/political instability, regulatory changes, protectionist laws, and foreign currency fluctuations, could adversely affect business.
• Manufacturing problems or failure to meet federal, state, or foreign manufacturing standards could lead to temporary cessation of operations, delays, and lost revenue.
• Reliance on single-source suppliers for critical components could harm the ability to meet demand in a timely and cost-effective manner.
• Disruption of critical information technology systems, infrastructure, data, or cyberattacks could harm business and financial condition.
• Actual or perceived failure to comply with privacy, cybersecurity, and data protection laws could result in proceedings, actions, or penalties.
• Implementation of artificial intelligence and machine learning technologies may result in legal, regulatory, or reputational risks.
• Continued consolidation in the healthcare industry could adversely affect business, financial condition, or results of operations.
• Insufficient coverage and reimbursement from third-party payors for product use, or a reduction in insured patients, could adversely affect demand and revenue.
• Lack of long-term clinical data for certain uses of products may lead to them being perceived as less safe or effective.
• Failures or disruptions at logistics providers could adversely impact business.
• Claims of intellectual property infringement or operating outside license scope could lead to significant expenses, liabilities, or sales prevention.
• Difficulty and cost in protecting intellectual property and proprietary technologies.
• Inability to raise capital or obtain financing in the future could prevent execution of growth strategy.
• Potential inability to fully utilize certain tax loss carryforwards.
• Unfavorable results of legal proceedings could materially and adversely affect financial condition.
• Volatility in common stock price could lead to losses for stockholders.
• Future issuances of common stock, including from warrant exercises, could dilute ownership interests.
• Conditional conversion features of the 2026 Notes, if triggered, may adversely affect financial condition and operating results.
• Provisions in corporate documents and debt agreements could discourage or prevent a takeover.
• Liquidity could be adversely impacted by adverse conditions in the financial markets.
• Operations are vulnerable to interruption or loss due to climate change, natural disasters, pandemics, terrorist acts, and other events beyond control.

Future Outlook

The company expects inflation and ongoing supply chain challenges, along with increased logistics costs, to continue impacting gross margins and cash from operations through at least calendar year 2025, and potentially longer. Reduced budgets and longer customer installation timelines in the United States are anticipated to negatively impact net revenue through fiscal year 2026. Sales to China are also expected to be adversely impacted through at least the first half of fiscal year 2026 due to tariff uncertainties. Management believes existing cash and cash equivalents, combined with available debt facilities, will be sufficient to fund operations for at least the next 12 months.

Management Comments

• We believe our treatment delivery, planning, and data management solutions provide better accuracy, flexibility, and control; fewer treatments with shorter treatment times; and the technology to expand beyond cancer.
• Our goal is to develop equipment and technology that enable physicians to deliver precise and accurate, customized, leading-edge treatments that help patients get back to living their lives, faster.
• Management is carefully evaluating our liquidity position, communicating with and monitoring the actions of our customers and suppliers, and reviewing our near-term financial performance as the uncertainty related to macroeconomic factors continues to unfold.
• We are committed to the safety and precision of our products and while no serious adverse health consequences have been reported in connection with recent recalls and the costs associated with each such recall were not material.

Industry Context

The medical device industry, particularly non-invasive cancer treatment, faces intense competition and rapid technological change. Accuray competes with large, well-capitalized companies like Varian Medical Systems (a Siemens Healthineers company) and Elekta AB, which hold significant market share. The industry is also seeing increased investment in new cancer treatments, including MRI-guided radiotherapy and proton therapy. Healthcare industry consolidation and evolving reimbursement policies continue to exert pressure on pricing and demand for medical devices. The company's strategy includes expanding into international markets, particularly China, which is identified as a large growth market for radiation oncology systems, despite trade tensions and regulatory complexities.

Comparison to Industry Standards

• The filing highlights that Accuray's CyberKnife and TomoTherapy platforms offer distinct advantages over conventional linear accelerators in terms of accuracy, flexibility, and control, aiming for fewer and shorter treatment times.
• The CyberKnife platform is noted as the only robotic, full-body SRS and SBRT delivery device on the market, offering sub-millimeter precision and real-time AI-driven motion tracking, which is presented as superior to traditional frame-based radiosurgery systems.
• TomoTherapy platforms, including Radixact, are positioned as uniquely capable of helical radiation therapy, integrating linear accelerator and CT imaging for precise dose conformity and minimizing healthy tissue exposure, with ClearRT kVCT imaging offering diagnostic-like quality compared to conventional cone-beam CT (CBCT) imaging.
• The company competes with industry leaders such as Varian Medical Systems, Inc. (a Siemens Healthineers company) and Elekta AB, who dominate the external beam radiation therapy market. While Accuray believes it competes favorably on price and value based on technology, its products are premium-priced systems.
• The filing does not provide specific comparative financial or operational benchmarks against named competitors (e.g., Varian, Elekta) but rather describes its products' technological differentiation and market positioning.

Management Changes

Corporate Governance

Legal Proceedings

• No probable and reasonably estimable material losses related to any current legal proceedings and claims.
• The company is under audit by the Indian tax authorities for the fiscal year 2021, with no expected material impact on consolidated financial statements.

Related Party Transactions

• Sales of products to the joint venture (CNNC Accuray) amounted to $101.6 million during FY2025.
• Sales of services to the joint venture (CNNC Accuray) amounted to $18.5 million during FY2025.
• Charge backs to the joint venture related to research and development were $1.5 million during FY2025.

Stakeholder Impact

• Shareholders face potential dilution from the exercise of 23.4 million warrants issued to lenders.
• Employees are subject to ongoing talent development programs, competitive compensation and benefits, but no company bonus plan payouts for FY2025 due to debt covenant concerns.
• Customers may experience delays in obtaining financing, construction, and regulatory approvals for system installations, impacting product delivery timelines.
• Suppliers face risks related to single-source reliance and macroeconomic factors affecting component supply and costs.
• Creditors (lenders) benefit from new secured debt facilities, but face risks related to the company's ability to meet financial covenants and manage high interest rates.

Next Steps

• Continue to increase physician adoption and patient awareness to drive utilization of systems.
• Expand the radiosurgery market through clinical development and collaboration.
• Innovate through clinical development and collaboration, including refining and upgrading systems.
• Increase sales and distribution capabilities in international markets, with focused additions of direct sales personnel and strategic partnerships.
• The China JV will continue to manufacture and sell locally branded radiotherapy devices and distribute other Accuray systems.
• Monitor and mitigate impacts from inflation, supply chain challenges, and tariffs.
• Evaluate liquidity position and anticipated capital requirements in light of macroeconomic conditions.
• Maintain compliance with financial covenants under the new Financing Agreement.
• Continue to develop new products and enhance existing products to meet customer needs and compete favorably.
• Monitor and enhance cybersecurity program, processes, techniques, and procedures.
• Assess and/or disclose climate metrics, risks, opportunities, policies, and practices as new legal or regulatory requirements emerge.

Key Dates

Recommendation

Accuray's recent debt refinancing and significant reduction in net loss, coupled with a return to positive cash flow from operations, are positive developments. The company's strategic focus on international markets, particularly China, and ongoing product innovation are also encouraging. However, the high interest rates and dilutive warrants associated with the new financing, along with persistent macroeconomic headwinds, tariff impacts, and customer-related delays, present substantial challenges. The company remains in a net loss position, and while improved, the path to sustained profitability is still uncertain. Given the mixed signals of financial improvement alongside significant ongoing risks and uncertainties, a 'hold' recommendation is appropriate for a seasoned investor or institution, suggesting a wait-and-see approach to monitor the company's ability to navigate these challenges and translate strategic initiatives into consistent profitability.

Keywords

Radiation Therapy, Oncology, Medical Devices, CyberKnife, TomoTherapy, Radixact, SRS, SBRT, IMRT, IGRT, ART, Debt Refinancing, Warrants, SEC Filing, Financial Results, Healthcare Technology, China Market, Supply Chain, Inflation, Cybersecurity, Regulatory Compliance